IL10 and melanoma: These are further supported by human studies in Hodgkin’s lymphoma, B cell lymphoma, melanoma, and hepatocellular carcinoma, where elevated serum IL-10 levels correlate with poor survival (Bohlen et al., 2000; Chau et al., 2000; Nemunaitis et al., 2001; Lech-Maranda et al., 2004).